Drug-Free Migraine Treatment CEFALY®: Publication of a Study Conducted on 2,313 Patients
The scientific journal "JOURNAL of HEADACHE and PAIN" publishes positive results from a clinical study conducted on 2,313 patients which confirms the high efficacy and safety of the medical device CEFALY ® migraine treatment
Jan 08, 2014, 09:00 ET
LIEGE, Belgium, January 8, 2014 /PRNewswire/ --
The efficacy and safety of the CEFALY ® medical device for migraine treatment had already been reported early 2013 in the scientific journal "Neurology" (Official Journal of the American Academy of Neurology). Today published data on a large number of individuals confirm the significant improvement for a majority of patients. Following 2 months of treatment, 54.4% of the patients described a very substantial improvement and decided to purchase the device. If we rule out those patients who didn't use the device or who only used it to a negligible degree, and take into account only regular users, the percentage of patients with a very significant improvement reaches 81%. Side effects are reported by only 4.3% of patients, all of which are minor and completely reversible. Therefore the effectiveness/safety ratio is excellent.
Current anti-migraine medications are only moderately effective and often not well tolerated. In addition, overuse of anti-migraine medications is an essential factor in the worsening of the disease and its development into chronic migraine. Cefaly ® is therefore a means of choice to treat a majority of migraine patients.
Cefaly® is an innovative medical device protected by a number of patents. It is the first device to offer external cranial neurostimulation. Cranial neurostimulation is a technique that has been used for a number of years in neurology, but this has been carried out using implantable neurostimulators (similar to pacemakers). The technological advances made by Cefaly means that there is now a simple, lightweight, economical and comfortable device available that offers migraine patients a method of treatment that is neither drug-based nor invasive.
A self-adhesive electrode is placed on the forehead and the device is positioned on this electrode, worn like a pair of glasses. Highly precise impulses are transmitted through the electrode to the nerve endings of the upper branch of the trigeminal nerve.
The Cefaly® medical device is available on the European market and in Canada; FDA approval for USA is expected in the coming months.
SOURCE CEFALY Technology
Share this article